Present Study Preliminary Tests
Sensitivity disks, ranging in potency from 0125 to 2 0 ,tg., were prepared from a sample of working standard of clomocycline containing 1,000 ,tg., using water as a diluent (clomocycline, unlike other tetracyclines is highly water soluble). Ten random strains of gonococci were tested against the disks; two strains were sensitive to 0 125 ,tg., five to 0-25 ,ug., two to 0 5 ,ug., and one to 1-0 Vg. It (Fig. 1) .
The two groups of patients differed also with regard to the alleged sources of infection (Fig. 2 Management and Follow-up A preliminary diagnosis was made on the results of Gram-stained smears of urethral discharge and in all cases specimens were submitted in transport medium for later inoculation of growth media suitable for N. gonorrhoeae and T. vaginalis. Disk sensitivity tests, using penicillin at four concentrations between 0-06 and 0 5 unit, streptomycin 10 ,ug., tetracycline 10 ,ug., clomocycline 1 .tg., were carried out on sub-cultures of organisms identified as N. gonorrhoeae.
Of the sixty patients with gonorrhoea, ten were treated with approximately 17 mg./kg. (1 capsule per 10 kg.) of clomocycline, six in a single dose and four in two doses taken at an interval of 6 to 8 hours; fifty were treated with 34 mg./kg. (2 capsules per 10 kg.), thirty taking this amount of the drug divided into two doses, 20 into three doses at intervals of 6 hours.
Of the fifty patients suffering from NGU, twenty received six 170 mg. capsules of clomocycline on each of 3 consecutive days, and thirty received six capsules on each of 4 days. The scheme of treatment was to give altemate patients three capsules twice a day or two capsules three times a day.
Patients were, as far as possible, followed up for 13 weeks. Most patients with gonorrhoea had no urethral discharge by the fourth day after treatment had started and, in those that had some discharge, gonococci were absent and pus-cells few. At the third visit, usually at the end of the second week, a prostatic bead was obtained and tested by smear and culture. The presence of gonococci in the urethral discharge before these tests were performed was regarded as failure of treatment. Patients who ceased to attend before the tests were counted as defaulters.
Patients in the NGU series were seen 1, 2, and 4 weeks after the beginning of treatment and the majority twice more at monthly intervals. The prostatic bead was usually obtained after the fourth week. Persistence of the urethral discharge for more than a week was regarded as a failure of treatment; its reappearance before the 28th day was regarded as an early relapse and after 28 days as a late relapse, irrespective of whether further sexual exposure had occurred. The remainder were looked upon as successfully treated.
Results Gonorrhoea (Table I) In the cases of nine of the ten patients who were treated with 17 mg./kg. clomocycline, gonococci were found in the urethral discharge at the first visit within 5 days; the success of this dose in the remaining case was confirmed at eight follow-up examinations.
Of the fifty patients treated with a total dose of 34 mg./kg., six failed to respond (12 per cent.), four in the group of thirty in which the dose was divided into two portions and two in the group of twenty in which it was divided into three portions. The failures could not be related to the results of in vitro sensitivity tests as measured by 1 jig. clomocycline disks. All strains of gonococci on this series were sensitive in vitro to 10 jig. tetracycline.
NGU developed in five patients between 8 and 20 days after successful treatment of gonorrhoea; T. vaginalis was cultured from the urethral discharge of one of these patients. In another patient with no evidence of a urethral discharge and clear urine, T. vaginalis was found in the fluid expressed by prostatic massage 3 weeks after treatment.
NGU (Table II, overleaf) In this series there were six immediate failures and three relapses within 4 weeks and two within 8 weeks of completing treatment. Five of the failures and two early relapses occurred in the group of twenty patients treated with clomocycline for 3 days, while only one failure, one early relapse, and two late relapses occurred in the group of those thirty patients who had been taking the drug for 4 days. The failures were equally distributed between patients who took 3 capsules twice daily and those who took two thrice daily.
Side-effects
All patients were carefully interrogated about possible side-effects after completing treatment. The unusually large doses of clomocycline used in this trial for the treatment of gonorrhoea were very well tolerated. 57 patients had no trouble whatever. Out of four patients weighing over 80 kg. who had received two doses of 8 capsules each, one vomited and one complained of nausea and epigastric pain lasting for an hour after the second dose. One patient who took three doses each of 5 capsules had shortlived nausea after each dose.
Antibiotics of the tetracycline group, taken for the treatment of NGU in generally accepted doses, rarely give rise to serious side-effects; but loose stools and sometimes pruritus ani are not uncommon complaints by fourth day of treatment. In our series of patients with NGU, only one reported loose motions on the fourth day.
Summary and Conclusion Clomocycline in varying doses was used for the treatment of 110 cases of urethritis in men, sixty of acute gonococcal urethritis, and fifty of nongonococcal urethritis.
In the gonorrhoea group ten patients were treated with a total of 17 mg./kg. (1 capsule per 10 kg.) in a single dose or two doses taken at an interval of 6-8 hours, and fifty were given 34 mg./kg. divided into two or three doses taken at 6-hourly intervals. Nine of ten cases failed to respond to 17 mg./kg. and six of fifty failed to respond to 34 mg./kg.
In the NGU group all patients received 6 capsules daily, twenty for 3 days and thirty for 4 days. 
